⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SVRA News
Savara Inc.
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
businesswire.com
SVRA
Hope with EAPs: 3 Things to Know About Expanded Access Programs for People with No Other Treatment Options
prnewswire.com
SVRA
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
globenewswire.com
SVRA
SLNO
INSM
PVLA
PTHS
Savara Announces New Employment Inducement Grant
businesswire.com
SVRA
Form 8-K
sec.gov
SVRA
Savara Announces Chief Financial and Administrative Officer Transition
businesswire.com
SVRA
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
businesswire.com
SVRA
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
businesswire.com
SVRA
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
businesswire.com
SVRA
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
businesswire.com
SVRA